Silica Corpora: Revolutionizing De Novo Antibody Therapy Design

Silica Corpora is a cutting-edge AI-driven platform developed by Silica Corpora GmbH, based in Berlin, Germany, that leverages proprietary protein Large Language Models (pLLMs) to accelerate the discovery and optimization of therapeutic antibodies. Designed for researchers and biotech teams, it enables fully de novo antibody generation using only amino acid sequences as input, significantly reducing reliance on animal testing and lowering development costs. The platform’s five integrated modules—Generator, Discriminator, Optimizer, Ep-Mapper, and Classifier—work synergistically to produce high-quality antibody candidates with strong binding affinity, improved developability, and precise epitope mapping, all validated through wet-lab testing. By integrating with existing in vitro workflows and learning from project-specific data, Silica Corpora delivers actionable insights from as few as 100 candidates, making it a powerful tool for advancing treatments for diseases with high unmet need.

Key Features:

• De Novo Antibody Generation: Creates novel antibody sequences (e.g., single domain antibodies, scFVs) from scratch using only amino acid inputs.
• Generator Module: Produces high-quality Complementary-Determining Regions (CDRs) with 85% to 98% mean similarity to known therapeutic antibodies.
• Discriminator Module: Predicts developability, stability, solubility, self-aggregation, and immunogenicity with 98% accuracy in distinguishing binders from non-binders.
• Optimizer Module: Adapts and enhances antibody candidates to meet specific target product profiles (TPPs) through intelligent mutation strategies.
• Ep-Mapper Module: Accurately predicts linear and conformational epitopes on antigens without requiring 3D structural data, achieving precision 0.68 and recall 0.71.
• Classifier Module: Predicts antibody-epitope binding with 95% success rate across 310 known antibodies.
• Data Integration: Seamlessly integrates with current in vitro workflows without needing new equipment, personnel, or expertise.
• Efficient Learning: Delivers significant insights from as few as 100 project-specific antibody candidates.
• Validation-Driven AI: Mitigates algorithmic hallucinations through iterative optimization and real-world wet-lab testing, prioritizing experimental results.
• Sustainable Innovation: Applies green principles to minimize waste and energy consumption in drug discovery.

Pricing: Silica Corpora operates on a freemium model, offering free access to foundational tools and data for initial exploration, with premium features and customized solutions available through partnership agreements.

Conclusion: Silica Corpora stands at the forefront of AI-powered drug discovery, delivering a highly accurate, efficient, and sustainable platform for designing next-generation antibody therapeutics—making it an indispensable ally for biotech innovators and research teams committed to faster, greener, and more accessible medicine development.